MetaCap

ProMIS Neurosciences Inc. (PMN)

NASDAQ: PMNHealth CareBiotechnology: Pharmaceutical PreparationsUSD

3.16-0.05 (-1.56%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PMN stock chart

Technical analysis

Key statistics

All statistics
Market cap
$28.43M
EPS (TTM)
-$6.50
52-week range
2.78 – 27.40
Day range
2.99 – 3.35
Volume / Avg
106.88K / 164.88K
Beta
—

52-week range

$2.78$27.40

PMN stock today

ProMIS Neurosciences (PMN) closed at $3.16 on Nov 20, down 1.56% (-$0.05), versus the S&P 500's 3.70% decline. Shares are 88.5% below their 52-week high of $27.40, set on Mar 5, 2026 and 13.7% above the 52-week low of $2.78, near the bottom of the past year's range. PMN is down 53.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 69.9%.

ProMIS Neurosciences has posted a net loss over the last twelve months (EPS of -$6.50), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About ProMIS Neurosciences

Company profile

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Neil K. Warma M.B.A.
Headquarters
Toronto, ON
Employees
10

Financial highlights

Full financials

ProMIS Neurosciences reported a net loss of $39.7 million, compared with net income of $2.8 million a year earlier. Diluted earnings per share came in at -$22.61, down from $2.63.

ProMIS Neurosciences annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-39.72M$2.78M$-13.21M$-18.06M$-9.79M
EPS (diluted)$-22.61$2.63$-1.07$-2.41$-1.69

Analyst forecast

Forecast

Consensus (8 analysts)

none

Avg. price target

$42.61+1248.42%

  • Strong buy 2
  • Buy 6
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $17.79High $98.01

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$6.00 vs $-1.26
Surprise
+576.19%

PMN news

All PMN news

ProMIS Neurosciences peers

Health Care sector
PMN peer companies
CompanyPrice% ChgMarket capCompare
AYTUAytu BioPharma Inc.2.660.00%$28.91Mvs PMN
ATHEAlterity Therapeutics Limited ADR1.52-8.16%$29.02Mvs PMN
RNTXRein Therapeutics Inc.0.3369-8.38%$29.06Mvs PMN
NNVCNanoViricides Inc.1.14-2.56%$29.13Mvs PMN
NXTCNextCure Inc.6.45-4.87%$29.53Mvs PMN
SERSerina Therapeutics Inc.1.12-6.67%$29.76Mvs PMN
EDSAEdesa Biotech Inc.2.00-8.05%$27.02Mvs PMN
NSRXNasus Pharma Ltd.2.29-10.20%$26.82Mvs PMN

Indexes, lists and sector

ProMIS Neurosciences stock FAQ

What is ProMIS Neurosciences's stock price today?

PMN last traded at $3.16 as of Nov 20, 4:00 PM EST, down 1.56% on the day. Prices are delayed at least 15 minutes.

Does ProMIS Neurosciences pay a dividend?

No. ProMIS Neurosciences does not currently pay a regular cash dividend.

Who is ProMIS Neurosciences's CEO?

Mr. Neil K. Warma M.B.A. is the chief executive officer of ProMIS Neurosciences Inc., which has about 10 employees.

Has PMN ever split its stock?

Yes. The most recent PMN stock split was a 1-for-25 split on Nov 28, 2025, one of 2 splits on record.

What is the PMN 52-week high?

The 52-week high for PMN is $27.40 and the 52-week low is $2.78. The stock is currently 88.5% below its high.

Compare PMN